Emergent
BioSolutions has a proven track record as a world-class provider of
contract manufacturing services for both bulk drug substances and
sterile injectable drug products.
Our
state-of-the-art single-use BDS facility enables turnkey upstream and
downstream support for mammalian, microbial, avian, insect and viral
cell lines. For sterile injectable drug products, our service offering
includes vials, syringes; liquid and lyophilized products.
We
currently produce 20 commercial products and have supported the
development/manufacture of more than 200 clinical candidates for our
clients.
Our facility has been inspected by a host of regulatory agencies worldwide, including the US, EU and Japan.
Visit Emergent BioSolutions at CPhI Worldwide October 4 - 6, 2016 | Barcelona, Spain | Stand #3D48 www.cphi.com/europe
|